Is the incidence of trigeminal neuralgia higher in patients with multiple sclerosis compared to the general population?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Multiple Sclerosis Significantly Increases Trigeminal Neuralgia Risk

Patients with multiple sclerosis have a 20-fold higher risk of developing trigeminal neuralgia compared to the general population 1. This dramatically elevated incidence makes trigeminal neuralgia one of the most common facial pain syndromes in MS patients, affecting approximately 1-2% of the MS population during their lifetime 2.

Key Epidemiological Facts

The association between MS and trigeminal neuralgia is well-established in clinical guidelines and research:

  • MS-related trigeminal neuralgia occurs as a symptomatic manifestation of the underlying demyelinating disease process 3
  • The condition is recognized as "secondary trigeminal neuralgia" when it results from MS-related nerve damage 4
  • MS patients develop trigeminal neuralgia at younger ages compared to the general population 1
  • Bilateral trigeminal pain is more common in MS patients than in those with idiopathic trigeminal neuralgia 1, 5

Clinical Implications

Pathophysiology Differences

In MS-related trigeminal neuralgia, the pain mechanism differs from classical trigeminal neuralgia:

  • Central demyelination of the trigeminal nerve pathways within the brainstem or pons is the primary cause, rather than neurovascular compression 6
  • Type 2 trigeminal neuralgia variants (with prolonged pain between sharp attacks) may be more common, suggesting central origin 3
  • The interaction between demyelination and potential neurovascular factors complicates management 6

Treatment Challenges

MS patients face unique therapeutic difficulties:

  • Reduced medication tolerance with increased side effects from anticonvulsants 1
  • Higher relapse rates after both medical and surgical interventions compared to idiopathic trigeminal neuralgia 1
  • Lower rates of sustained pain relief requiring multiple procedures over time 1
  • Higher recurrence rates after percutaneous procedures (significantly elevated, p < 0.05) 1

Prognostic Factors

Patients with higher disability at trigeminal neuralgia onset experience:

  • More frequent bilateral pain 5
  • Earlier need for surgical intervention 5
  • Less likelihood of medication discontinuation due to pain remission 5
  • Longer duration requiring preventive medications (77% still on medication after mean 8 years) 5

Clinical Recognition

When evaluating facial pain in MS patients, maintain high suspicion for trigeminal neuralgia given the 20-fold increased risk. The diagnosis should prompt:

  • MRI evaluation to assess for demyelinating plaques in the trigeminal pathway and rule out neurovascular compression 7
  • Early consideration of the full treatment spectrum, recognizing that MS-related cases are more refractory
  • Anticipation of higher recurrence rates and need for repeat interventions compared to classical trigeminal neuralgia

The substantially elevated incidence in MS patients underscores the importance of screening for this complication during routine MS care, as early recognition and appropriate management can significantly impact quality of life despite the challenging treatment course.

References

Research

Trigeminal neuralgia management in patients with multiple sclerosis: A systematic review of approaches and outcomes.

Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, 2025

Research

Trigeminal neuralgia in multiple sclerosis: proposal of surgical flowchart and long-term outcome evaluation in a mono-istitutional cohort.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2024

Guideline

acr appropriateness criteria® cranial neuropathy: 2022 update.

Journal of the American College of Radiology, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.